{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:14:34Z","timestamp":1784546074295,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Qiqihar Academy of Medical Science in 2021","award":["QMSI2020L-01"],"award-info":[{"award-number":["QMSI2020L-01"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174097"],"award-info":[{"award-number":["82174097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Construction Project of Dominant Characteristic Disciplines of Qiqihar Medical University","award":["QYZDXK-001"],"award-info":[{"award-number":["QYZDXK-001"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejpb.2025.114779","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T11:05:06Z","timestamp":1749294306000},"page":"114779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Overcoming drug resistance in osteosarcoma with MTX-CuB-NLC: An in vitro and in vivo study"],"prefix":"10.1016","volume":"214","author":[{"given":"Hao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingqi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifu","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiyan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2025.114779_b0005","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma: current treatment and a collaborative pathway to success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2025.114779_b0010","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1200\/JCO.2006.07.7776","article-title":"Multiple drug resistance in osteogenic sarcoma: INT0133 from the children's oncology group","volume":"25","author":"Schwartz","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2025.114779_b0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","article-title":"Osteosarcoma","volume":"8","author":"Beird","year":"2022","journal-title":"J. Nat Rev Dis Primers."},{"key":"10.1016\/j.ejpb.2025.114779_b0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-319-04843-7_6","article-title":"MicroRNAs in osteosarcomagenesis","volume":"804","author":"Kafchinski","year":"2014","journal-title":"J Advances in Experimental Medicine & Biology."},{"key":"10.1016\/j.ejpb.2025.114779_b0025","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/030089161009600411","article-title":"Radiotherapy in the treatment of primary osteosarcoma\u2013a single center experience","volume":"96","author":"Oertel","year":"2010","journal-title":"J. Tumori."},{"key":"10.1016\/j.ejpb.2025.114779_b0030","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S","article-title":"Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery","volume":"43","author":"Rosen","year":"1979","journal-title":"J. Cancer."},{"key":"10.1016\/j.ejpb.2025.114779_b0035","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/230949900801600211","article-title":"Tumour volume and lung metastasis in patients with osteosarcoma","volume":"16","author":"Munajat","year":"2008","journal-title":"J. Orthopaedic Surgery (Hong Kong)"},{"key":"10.1016\/j.ejpb.2025.114779_b0040","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s13277-015-3181-0","article-title":"Research progress on the mulitidrug resistance mechanisms of osteosarcoma chemotherapy and reversal","volume":"36","author":"Li","year":"2015","journal-title":"J. Tumour Biology."},{"key":"10.1016\/j.ejpb.2025.114779_b0045","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3892\/or.2013.2658","article-title":"Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt\/beta-catenin signaling","volume":"30","author":"Liu","year":"2013","journal-title":"J. Oncology Reports."},{"key":"10.1016\/j.ejpb.2025.114779_b0050","article-title":"FAP-activated liposomes achieved specific macropinocytosis uptake by pancreatic stellate cells for efficient desmoplasia reversal","volume":"495","author":"Ziqing","year":"2024","journal-title":"J. Chem. Eng. J."},{"key":"10.1016\/j.ejpb.2025.114779_b0055","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jconrel.2024.01.055","article-title":"SiATG5-loaded cancer cell membrane-fused liposomes induced increased uptake of albumin-bound chemotherapeutics by pancreatic cancer cells","volume":"367","author":"Yan","year":"2024","journal-title":"J. Control Release."},{"key":"10.1016\/j.ejpb.2025.114779_b0060","first-page":"68","article-title":"Nano-formulations for tumour targeting: research advances","volume":"41","author":"Wei","year":"2014","journal-title":"J. Int. J. Pharm. Sci. Rev. Res."},{"key":"10.1016\/j.ejpb.2025.114779_b0065","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrd2591","article-title":"Strategies in the design of nanoparticles for therapeutic applications","volume":"9","author":"Petros","year":"2010","journal-title":"J. Nat. Rev. Drug Discovery."},{"key":"10.1016\/j.ejpb.2025.114779_b0070","first-page":"163","article-title":"Recent strategies towards the surface modification of: liposomes:an innovative approach for different clinical applications","volume":"10","author":"Khan","year":"2020","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.ejpb.2025.114779_b0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12951-017-0326-x","article-title":"Dual-drug loaded nanoneedles with targeting property for efficient cancer therapy","volume":"15","author":"Yang","year":"2017","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejpb.2025.114779_b0080","first-page":"4623","article-title":"The modulation of local and systemic anti-tumor immune response induced by methotrexate nanoconjugate in murine MC38 colon carcinoma and B16 F0 melanoma tumor models","volume":"13","author":"Szczygie\u0142","year":"2023","journal-title":"J. Am J Cancer Res."},{"key":"10.1016\/j.ejpb.2025.114779_b0085","doi-asserted-by":"crossref","unstructured":"B.N.Cronstein, et al., Methotrexate and its mechanisms of action in inflammatory arthritis, Nat Rev Rheumatol. 16 (2020) 145-154, doi: 10.1038\/s41584-020-0373-9.","DOI":"10.1038\/s41584-020-0373-9"},{"key":"10.1016\/j.ejpb.2025.114779_b0090","first-page":"247","article-title":"Mechanisms of action of methotrexate","volume":"47","author":"Genestier","year":"2000","journal-title":"J Bull. Rheumatic Diseases."},{"key":"10.1016\/j.ejpb.2025.114779_b0095","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1136\/annrheumdis-2020-217207","article-title":"Methotrexate: what are the true risks of treatment?","volume":"79","author":"Strangfeld","year":"2020","journal-title":"J. Ann Rheum Dis."},{"key":"10.1016\/j.ejpb.2025.114779_b0100","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.1997.15.5.2125","article-title":"Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction","volume":"15","author":"Widemann","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2025.114779_b0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13273-016-0005-2","article-title":"Ethanol enhances cucurbitacin B-induced apoptosis by inhibiting cucurbitacin B-induced autophagy in Lo2 hepatocytes","volume":"12","author":"Ding","year":"2016","journal-title":"J. Mol Cell Toxicol."},{"key":"10.1016\/j.ejpb.2025.114779_b0110","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s13277-015-3773-8","article-title":"Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B","volume":"37","author":"El-Senduny","year":"2016","journal-title":"J. Tumour Biol."},{"key":"10.1016\/j.ejpb.2025.114779_b0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.biocel.2016.05.014","article-title":"Cucurbitacin B inhibits breast cancer metastasis and angiogenesis through VEGF-mediated suppression of FAK\/MMP-9 signaling axis","volume":"77","author":"Sinha","year":"2016","journal-title":"J. Int. Biochem. Cell Biol."},{"key":"10.1016\/j.ejpb.2025.114779_b0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3892\/or.2017.5648","article-title":"Cucurbitacin B induces autophagy and apoptosis by suppressing CIP2A\/PP2A\/mTORC1 signaling axis in human cisplatin resistant gastric cancer cells","volume":"38","author":"Liu","year":"2017","journal-title":"J. Oncol. Rep."},{"key":"10.1016\/j.ejpb.2025.114779_b0125","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1158\/1538-7445.AM2016-3763","article-title":"Abstract 3763: Cucurbitacin B targets EGFR-mutant lung cancer cells via activation of sestrin-3","volume":"76","author":"Khan","year":"2016","journal-title":"J. Can. Res."},{"key":"10.1016\/j.ejpb.2025.114779_b0130","doi-asserted-by":"crossref","first-page":"9251","DOI":"10.12659\/MSM.911594","article-title":"Cucurbitacin B inhibits the hippo-YAP signaling pathway and exerts anticancer activity in colorectal cancer cells","volume":"24","author":"Chai","year":"2018","journal-title":"J. Med Sci Monit."},{"key":"10.1016\/j.ejpb.2025.114779_b0135","article-title":"Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest","volume":"126","author":"Li","year":"2024","journal-title":"J. Phytomedicine."},{"key":"10.1016\/j.ejpb.2025.114779_b0140","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1016\/j.apsb.2022.05.021","article-title":"Cucurbitacin B-induced G2\/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78-FOXM1-KIF20A pathway","volume":"12","author":"Wei","year":"2022","journal-title":"J. Acta Pharm Sin b."},{"key":"10.1016\/j.ejpb.2025.114779_b0145","first-page":"19","article-title":"Cucurbitacin B and cancer intervention: chemistry, biology and mechanisms (review)","volume":"52","author":"Garg","year":"2018","journal-title":"J. Int. J. Oncol."},{"key":"10.1016\/j.ejpb.2025.114779_b0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejphar.2017.01.006","article-title":"Cucurbitacin B purified from Ecballium elaterium (L.) a. rich from Tunisia inhibits \u03b15\u03b21 integrin-mediated adhesion, migration, proliferation of human glioblastoma cell line and angiogenesis","volume":"15","author":"Touihri-Barakati","year":"2017","journal-title":"J. Eur. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114779_b0155","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1021\/acscentsci.2c00107","article-title":"Allosteric regulation of IGF2BP1 as a novel strategy for the activation of tumor immune microenvironment","volume":"24","author":"Liu","year":"2022","journal-title":"J. ACS Cent Sci."},{"key":"10.1016\/j.ejpb.2025.114779_b0160","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3892\/or.2016.4892","article-title":"Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7\/adriamycin cells","volume":"36","author":"Cai","year":"2016","journal-title":"J. Oncol Rep."},{"key":"10.1016\/j.ejpb.2025.114779_b0165","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3892\/ol.2017.6148","article-title":"Inhibition of paclitaxel resistance and apoptosis induction by cucurbitacin B in ovarian carcinoma cells","volume":"14","author":"Qu","year":"2017","journal-title":"J. Oncol Lett."},{"key":"10.1016\/j.ejpb.2025.114779_b0170","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2011.03.001","article-title":"Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma","volume":"306","author":"Lee","year":"2011","journal-title":"J Can. Letters."},{"key":"10.1016\/j.ejpb.2025.114779_b0175","doi-asserted-by":"crossref","DOI":"10.2165\/00003088-200342020-00003","article-title":"Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases[J]","volume":"42","author":"Grim","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2025.114779_b0180","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.canlet.2010.01.029","article-title":"Cucurb-itacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral admin-istrati on [J]","volume":"11","author":"Chan","year":"2010","journal-title":"Can. Lett."},{"key":"10.1016\/j.ejpb.2025.114779_b0185","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"J. Can. Res."},{"key":"10.1016\/j.ejpb.2025.114779_b0190","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.7150\/thno.49577","article-title":"The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy","volume":"10","author":"Shi","year":"2020","journal-title":"J. Theranostics"},{"key":"10.1016\/j.ejpb.2025.114779_b0195","first-page":"1","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2012","journal-title":"J. Adv. Drug. Del. Rev."},{"key":"10.1016\/j.ejpb.2025.114779_b0200","first-page":"2","article-title":"Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches","volume":"347","author":"Wu","year":"2014","journal-title":"J. Can. Lett."},{"key":"10.1016\/j.ejpb.2025.114779_b0205","doi-asserted-by":"crossref","unstructured":"Qui\u00f1onero, Francisco, et al., Combining olaparib and ascorbic acid on nanoparticles to enhance the drug toxic effects in pancreatic cancer, J. Int. J. Nanomed. (2023). doi: 10.2147\/IJN.S415631.","DOI":"10.2147\/IJN.S415631"},{"key":"10.1016\/j.ejpb.2025.114779_b0210","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.2147\/DDDT.S317454","article-title":"Dual-functional peptide driven liposome codelivery system for efficient treatment of doxorubicin-resistant breast cancer","volume":"15","author":"Ahmed","year":"2021","journal-title":"J. Drug Design, Dev. Therapy"},{"key":"10.1016\/j.ejpb.2025.114779_b0215","doi-asserted-by":"crossref","unstructured":"Jiang, Wenwei, et al. 2D-CuPd nanozyme overcome tamoxifen resistance in breast cancer by regulating the PI3K\/AKT\/mTOR pathway, J. Biomaterials. (2022).doi: 10.1016\/j.biomaterials.2022.121986.","DOI":"10.1016\/j.biomaterials.2022.121986"},{"key":"10.1016\/j.ejpb.2025.114779_b0220","doi-asserted-by":"crossref","unstructured":"Chen, Chenglong, Xie, Lu, Ren, Tingting, Huang, Yi, Xu, Jie, Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs, J. Can. Lett. 500 (2020) 1\u201310, doi: 10.1016\/j.canlet.2020.12.024.","DOI":"10.1016\/j.canlet.2020.12.024"},{"key":"10.1016\/j.ejpb.2025.114779_b0225","first-page":"18","article-title":"Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies","volume":"21","author":"Lilienthal","year":"2020","journal-title":"J. Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2025.114779_b0230","doi-asserted-by":"crossref","unstructured":"Liu, Ying, Li, Qing, Bai, Qian, et al., Advances of smart nano-drug delivery systems in osteosarcoma treatment, J. Mater. Chem. B. 9 (2021), doi: 10.3892\/ol.2016.4596.","DOI":"10.1039\/D1TB00566A"},{"key":"10.1016\/j.ejpb.2025.114779_b0235","doi-asserted-by":"crossref","unstructured":"Khdair, Ayman, Handa, et al., Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro, J. Eur. J. Pharm. Biopharm. 71 (2008), doi: 10.1016\/j.ejpb.2008.08.017.","DOI":"10.1016\/j.ejpb.2008.08.017"},{"key":"10.1016\/j.ejpb.2025.114779_b0240","doi-asserted-by":"crossref","unstructured":"De Jong, Wim H., Borm, et al., Drug delivery and nanoparticles:applications and hazards, J. Int. J. Nanomed. 3 (2008) 133\u201349, doi: 10.2147\/ijn.s596.","DOI":"10.2147\/IJN.S596"},{"issue":"21","key":"10.1016\/j.ejpb.2025.114779_b0245","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.3390\/ijms21186885","article-title":"Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies","volume":"2020","author":"Lilienthal","year":"2020","journal-title":"J. Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2025.114779_b0250","doi-asserted-by":"crossref","unstructured":"Yuan, Renyikun, Yuan, et al., Cucurbitacin B inhibits TGF-\u03b21-induced epithelial-mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K\/Akt\/mTOR pathways, J. Chinese medicine 17 (2022) 24.","DOI":"10.1186\/s13020-022-00581-z"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125001560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125001560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:40:20Z","timestamp":1762332020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125001560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":50,"alternative-id":["S0939641125001560"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114779","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming drug resistance in osteosarcoma with MTX-CuB-NLC: An in vitro and in vivo study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114779"}}